You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.
GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmacare Holdings Limited (JSE: APN) and certain of its subsidiaries (“Aspen”), which were the subject of announcements by both companies on 12 September 2016.
ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention
First injectable to be studied for efficacy in pre-exposure prophylaxis
GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) when compared to therapy with the once-daily dual combination therapy, Relvar/Breo® (FF/VI), as a treatment for patients with asthma.
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Type II variation and extension applications to reduce the weight and age limit for the treatment of HIV in children and adolescents with Tivicay (dolutegravir) from at least 40kg to at least 15kg, in ages six to less than 12 years old, and to register new dose strengths of 10mg and 25mg oral tablets.